REHOVOT, Israel & PHILADELPHIA & LAVAL, Quebec--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDQ:ROSG), the leading developer of microRNA-based molecular diagnostics, and Warnex Medical Laboratories, a division of Warnex Inc. (TSX:WNX), announced today they have signed an exclusive distribution agreement in Canada for three currently-available diagnostic tests. Under the terms of the agreement, Warnex will market Rosetta Genomics’ miRview™ tests. Samples will be sent from Canada to Rosetta Genomics’ Philadelphia-based CLIA-certified laboratory for analysis. The terms of the deal were not disclosed.
